On May 17, 2022 OBI Pharma, Inc. (TPEx: 4174), a leader in First-in-Class Cancer therapeutics, reported that data highlighting ongoing clinical studies targeting Globo H and AKR1C3 in different tumor types will be presented at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) meeting from June 3–7, 2022 in Chicago, IL (USA) (Press release, OBI Pharma, MAY 17, 2022, View Source [SID1234614782]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
These studies will be presented by the lead investigators of OBI Pharma’s first-in-class anti-Globo H cancer vaccine (Adagloxad Simolenin) and Antibody Drug Conjugate (OBI-999), and AKR1C3 targeting prodrug (OBI-3424).
"OBI Pharma is proud to have posters at ASCO (Free ASCO Whitepaper) highlighting the ongoing clinical trials with our first-in-class cancer therapeutics, Adagloxad Simolenin, OBI-999, and OBI-3424. We look forward to providing updates of our current clinical studies, which we believe could offer potential therapeutic benefits for patients whose cancer cells show Globo H or AKR1C3 expression. We are also excited to host an OBI Pharma exhibit booth to meet with investigators and meeting participants" stated Ming-Tain Lai, PhD, Chief Scientific Officer at OBI Pharma.
Poster / Abstract: TPS611
Title: A phase 3, randomized, open-label study of the anti-Globo H vaccine Adagloxad Simolenin/OBI-821 in the adjuvant treatment of high-risk, early-stage, Globo H-positive triple-negative breast cancer.
Session Title: Breast Cancer—Local/Regional/Adjuvant
Presenter: Hope S. Rugo, MD, FASCO University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
Session Date and Time: Monday, June 6, 2022. 8:00 a.m. – 11:00 a.m. Central Time
Poster / Abstract: 3029
Title: First-in-Human Study of OBI-999: a Globo H-Targeting Antibody-Drug Conjugate in Patients with Advanced Solid Tumors
Session Title: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Presenter: Apostolia Maria Tsimberidou PhD, MD, The University of Texas MD Anderson Cancer Center, Houston, TX.
Session Date and Time: Sunday, June 5, 2022. 8:00 a.m. – 11:00 a.m. Central Time
Poster / Abstract: 3030
Title: Safety, Pharmacokinetics, and Clinical Activity of OBI-3424, an AKR1C3-Activated Prodrug, in Patients with Advanced or Metastatic Solid Tumors: A Phase 1 Dose-Escalation Study
Session Title: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Presenter: Apostolia Maria Tsimberidou PhD, MD,The University of Texas MD Anderson Cancer Center, Houston, TX.
Session Date and Time: Sunday, June 5, 2022. 8:00 a.m. – 11:00 a.m. Eastern Time
The above poster presentations will be available online at www.obipharma.com on June 6, 2022.
OBI Exhibit Booth # 3144 (McCormick Center, Chicago, IL).
OBI Pharma personnel will be available to discuss our Cancer pipeline under clinical development for ASCO (Free ASCO Whitepaper) meeting attendees only from June 6-8 from 9am to 5 pm CST.